2-[2-benzhydryloxyethyl(methyl)amino]-1-phenylpropan-1-ol;hydron;chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[2-benzhydryloxyethyl(methyl)amino]-1-phenylpropan-1-ol;hydron;chloride
• 化学式: C25H30ClNO2
• 分子量: 412.0
• InChiKey: WKZITTRQXFNUNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.27
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  32.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• DRUG PREPARATIONS
  申请人：SSP Co., Ltd.

  公开号：EP1391200A1

  公开（公告）日：2004-02-25

  Drug preparations characterized by containing fudosteine and an antitussive. These preparations are drugs to be used for common cold, etc. which have improved antitussive and sputum-removal effects.

  药物制剂，其特点是含有夫多斯汀和一种止咳药。这些制剂是用于治疗普通感冒等的药物，具有更好的止咳和化痰效果。
• MEDICINAL COMPOSITIONS
  申请人：SSP Co., Ltd.

  公开号：EP1391201A1

  公开（公告）日：2004-02-25

  Medicinal compositions characterized by containing fudosteine and an antipyretic/analgesic. These medicinal compositions are medicinal compositions to be used for common cold, etc. which have improved sputum-removal and antiinflammatory effects.

  药用复方制剂，其特点是含有呋喃妥因和解热镇痛药。这些药剂组合物是用于普通感冒等的药剂组合物，具有更好的化痰和消炎效果。
• New pharmaceutical compositions containing a combination of ambroxol or bromhexine and isopropamide iodide
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1417961A1

  公开（公告）日：2004-05-12

  The present invention relates to novel pharmaceutical compositions comprising as pharmacologically active compounds a combination of an expectorant-effective amount of bromhexine or ambroxol or a pharmacologically acceptable salt thereof and a parasympatholytic (anticholinergic)-effective amount of isopropamide iodide. Qualitative and quantitative formula of this invention includes pharmaceutically acceptable carriers or excipients. The formulation further comprises suitable pharmaceutically acceptable carriers or excipients. In addition, this invention is related to the usage of these compounds for the various symptoms caused by the common cold. Especially, the composition of the present invention is effective in the treatment of sputum and/or runny nose among the various symptoms caused by the common cold.

  本发明涉及新型药物组合物，其药理活性化合物包括祛痰有效量的溴己新或氨溴索或其药理上可接受的盐与副交感神经溶解（抗胆碱能）有效量的碘化异丙酰胺的组合。 本发明的定性和定量配方包括药学上可接受的载体或赋形剂。 制剂还包括合适的药学上可接受的载体或赋形剂。 此外，本发明还与这些化合物用于治疗普通感冒引起的各种症状有关。 特别是，本发明的组合物对治疗普通感冒引起的各种症状中的痰和/或流鼻涕有效。
• POROUS CELLULOSE AGGREGATE AND MOLDING COMPOSITION THEREOF
  申请人：Asahi Kasei Chemicals Corporation

  公开号：EP1873196A1

  公开（公告）日：2008-01-02

  A porous cellulose aggregate characterized by having a secondary aggregate structure resulting from aggregation of primary cellulose particles, having a pore volume within a particle of 0.265 to 2.625 cm3/g, containing I-type crystals and having an average particle size of over 30 to 250 µm, a specific surface area of 0.1 to less than 20 m2/g, a repose angle of 25° to less than 44° and a swelling degree of 5% or more, and characterized by having the property of disintegrating in water.

  一种多孔纤维素聚合体，其特征在于具有由初级纤维素颗粒聚合而成的次级聚合体结构，颗粒内的孔隙体积为 0.265 至 2.625 cm3/g，含有 I 型晶体，平均粒径大于 30 至 250 µm，比表面积为 0.1 至小于 20 m2/g，倾角为 25 至小于 44°，膨胀度为 5%或以上，并具有遇水崩解的特性。
• CELLULOSE POWDER HAVING EXCELLENT SEGREGATION PREVENTIVE EFFECT, AND COMPOSITIONS THEREOF
  申请人：Asahi Kasei Chemicals Corporation

  公开号：EP2287234A1

  公开（公告）日：2011-02-23

  With regard to compositions derived from active ingredients and other additives in medical, food and industrial fields, there have been problems that the active ingredients cannot be uniformly mixed, and that the active ingredients become segregated and lose uniformity as the active ingredients undergo transport, input, and filling processes. There is provided a cellulose powder which improves the uniformity of compositions containing active ingredients or other additives to prevent segregation of the active ingredients, wherein the cellulose powder contains cellulose I type crystals, has an average particle diameter of less than 30 µm, a powder density of 0.1 to 0.45 g/cm3, a tapping density of 0.1 to 0.5 g/cm3, a repose angle of 35 to 50°, a specific surface of more than or equal to 0.1 m2/g and less than 20 m2/g, an internal friction angle of 36 to 42°, and is a cellulose powder including a secondary flocculation structure in which primary particles are flocculated.

  关于医疗、食品和工业领域中由活性成分和其他添加剂制成的组合物，一直存在着活性成分不能均匀混合，以及活性成分在运输、输入和灌装过程中发生分离和失去均匀性的问题。本发明提供了一种纤维素粉末，可改善含有活性成分或其他添加剂的组合物的均匀性，防止活性成分的偏析，其中纤维素粉末含有纤维素 I 型晶体，平均颗粒直径小于 30 µm，粉末密度为 0.1至0.45克/立方厘米，攻丝密度为0.1至0.5克/立方厘米，倾伏角为35至50°，比表面大于或等于0.1平方米/克但小于20平方米/克，内摩擦角为36至42°，并且是一种纤维素粉末，包括二级絮凝结构，其中初级粒子被絮凝。